Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis

Loredana La Mantia, Carlo Di Pietrantonj, Marco Rovaris, Giulio Rigon, Serena Frau, Francesco Berardo, Anna Gandini, Anna Longobardi, Bianca Weinstock-Guttman, Alberto Vaona

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Interferon β (INFβ) and glatiramer acetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS). However, it is still unclear whether they have different efficacy. We performed a systematic search of head-to-head trials for gaining objective reliable data to compare the two drugs, using the Cochrane Collaboration methodology. We identified five randomised-controlled trials (RCTs) (2858 participants) comparing directly INFβ versus GA in RRMS. All studies were at high risk for attrition bias. Both therapies showed similar efficacy at 24 months, considering clinical ( patients with relapse or progression) and one MRI activity (enhancing lesions) measure. At 3 years, evidence from a single study showed that the relapse rate was higher in the INFβ group than in the GA group (risk ratio 1.40, 95% CI 1.13 to 1.74, p 0.002). However, the average reduction in T2-weighted and T1-weighted lesion volume was significantly greater in the INFβ group than in the GA group (mean difference (MD) -0.58, 95% CI -0.99 to -0.18, p 0.004, and MD -0.20, 95% CI -0.33 to -0.07, p 0.003, respectively). The number of participants who dropped out of the studies because of adverse events was similar in the two groups. These data support clinicians in the use of these therapies, based on their similar safety and efficacy in the prevention of disease activity, although the different effect on MRI measures and the different tolerability might have a role in the therapeutic choice at the individual level.

Original languageEnglish
Pages (from-to)1016-1020
Number of pages5
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume86
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Interferons
Recurrence
Therapeutics
Randomized Controlled Trials
Odds Ratio
Safety
Glatiramer Acetate
Efficacy
Multiple Sclerosis
Pharmaceutical Preparations
Lesion
Relapse
Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery
  • Arts and Humanities (miscellaneous)
  • Medicine(all)

Cite this

Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis. / La Mantia, Loredana; Di Pietrantonj, Carlo; Rovaris, Marco; Rigon, Giulio; Frau, Serena; Berardo, Francesco; Gandini, Anna; Longobardi, Anna; Weinstock-Guttman, Bianca; Vaona, Alberto.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 86, No. 9, 01.09.2015, p. 1016-1020.

Research output: Contribution to journalArticle

La Mantia, L, Di Pietrantonj, C, Rovaris, M, Rigon, G, Frau, S, Berardo, F, Gandini, A, Longobardi, A, Weinstock-Guttman, B & Vaona, A 2015, 'Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis', Journal of Neurology, Neurosurgery and Psychiatry, vol. 86, no. 9, pp. 1016-1020. https://doi.org/10.1136/jnnp-2014-309243
La Mantia, Loredana ; Di Pietrantonj, Carlo ; Rovaris, Marco ; Rigon, Giulio ; Frau, Serena ; Berardo, Francesco ; Gandini, Anna ; Longobardi, Anna ; Weinstock-Guttman, Bianca ; Vaona, Alberto. / Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis. In: Journal of Neurology, Neurosurgery and Psychiatry. 2015 ; Vol. 86, No. 9. pp. 1016-1020.
@article{d368e05a6beb42cf99235dfaa094f454,
title = "Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis",
abstract = "Interferon β (INFβ) and glatiramer acetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS). However, it is still unclear whether they have different efficacy. We performed a systematic search of head-to-head trials for gaining objective reliable data to compare the two drugs, using the Cochrane Collaboration methodology. We identified five randomised-controlled trials (RCTs) (2858 participants) comparing directly INFβ versus GA in RRMS. All studies were at high risk for attrition bias. Both therapies showed similar efficacy at 24 months, considering clinical ( patients with relapse or progression) and one MRI activity (enhancing lesions) measure. At 3 years, evidence from a single study showed that the relapse rate was higher in the INFβ group than in the GA group (risk ratio 1.40, 95{\%} CI 1.13 to 1.74, p 0.002). However, the average reduction in T2-weighted and T1-weighted lesion volume was significantly greater in the INFβ group than in the GA group (mean difference (MD) -0.58, 95{\%} CI -0.99 to -0.18, p 0.004, and MD -0.20, 95{\%} CI -0.33 to -0.07, p 0.003, respectively). The number of participants who dropped out of the studies because of adverse events was similar in the two groups. These data support clinicians in the use of these therapies, based on their similar safety and efficacy in the prevention of disease activity, although the different effect on MRI measures and the different tolerability might have a role in the therapeutic choice at the individual level.",
author = "{La Mantia}, Loredana and {Di Pietrantonj}, Carlo and Marco Rovaris and Giulio Rigon and Serena Frau and Francesco Berardo and Anna Gandini and Anna Longobardi and Bianca Weinstock-Guttman and Alberto Vaona",
year = "2015",
month = "9",
day = "1",
doi = "10.1136/jnnp-2014-309243",
language = "English",
volume = "86",
pages = "1016--1020",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis

AU - La Mantia, Loredana

AU - Di Pietrantonj, Carlo

AU - Rovaris, Marco

AU - Rigon, Giulio

AU - Frau, Serena

AU - Berardo, Francesco

AU - Gandini, Anna

AU - Longobardi, Anna

AU - Weinstock-Guttman, Bianca

AU - Vaona, Alberto

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Interferon β (INFβ) and glatiramer acetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS). However, it is still unclear whether they have different efficacy. We performed a systematic search of head-to-head trials for gaining objective reliable data to compare the two drugs, using the Cochrane Collaboration methodology. We identified five randomised-controlled trials (RCTs) (2858 participants) comparing directly INFβ versus GA in RRMS. All studies were at high risk for attrition bias. Both therapies showed similar efficacy at 24 months, considering clinical ( patients with relapse or progression) and one MRI activity (enhancing lesions) measure. At 3 years, evidence from a single study showed that the relapse rate was higher in the INFβ group than in the GA group (risk ratio 1.40, 95% CI 1.13 to 1.74, p 0.002). However, the average reduction in T2-weighted and T1-weighted lesion volume was significantly greater in the INFβ group than in the GA group (mean difference (MD) -0.58, 95% CI -0.99 to -0.18, p 0.004, and MD -0.20, 95% CI -0.33 to -0.07, p 0.003, respectively). The number of participants who dropped out of the studies because of adverse events was similar in the two groups. These data support clinicians in the use of these therapies, based on their similar safety and efficacy in the prevention of disease activity, although the different effect on MRI measures and the different tolerability might have a role in the therapeutic choice at the individual level.

AB - Interferon β (INFβ) and glatiramer acetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS). However, it is still unclear whether they have different efficacy. We performed a systematic search of head-to-head trials for gaining objective reliable data to compare the two drugs, using the Cochrane Collaboration methodology. We identified five randomised-controlled trials (RCTs) (2858 participants) comparing directly INFβ versus GA in RRMS. All studies were at high risk for attrition bias. Both therapies showed similar efficacy at 24 months, considering clinical ( patients with relapse or progression) and one MRI activity (enhancing lesions) measure. At 3 years, evidence from a single study showed that the relapse rate was higher in the INFβ group than in the GA group (risk ratio 1.40, 95% CI 1.13 to 1.74, p 0.002). However, the average reduction in T2-weighted and T1-weighted lesion volume was significantly greater in the INFβ group than in the GA group (mean difference (MD) -0.58, 95% CI -0.99 to -0.18, p 0.004, and MD -0.20, 95% CI -0.33 to -0.07, p 0.003, respectively). The number of participants who dropped out of the studies because of adverse events was similar in the two groups. These data support clinicians in the use of these therapies, based on their similar safety and efficacy in the prevention of disease activity, although the different effect on MRI measures and the different tolerability might have a role in the therapeutic choice at the individual level.

UR - http://www.scopus.com/inward/record.url?scp=84940646346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940646346&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2014-309243

DO - 10.1136/jnnp-2014-309243

M3 - Article

C2 - 25550414

AN - SCOPUS:84940646346

VL - 86

SP - 1016

EP - 1020

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 9

ER -